

SANDOZ

Tyruko▼ (natalizumab) 300 mg concentrate for solution for infusion

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Physician Information and Management Guidelines for Patients With Multiple Sclerosis Receiving TYRUKO Therapy

Treatment with TYRUKO is to be initiated and monitored by specialised physicians experienced in the diagnosis and management of neurological conditions like Multiple Sclerosis (MS) with timely access to magnetic resonance imaging (MRI).

Date of MHRA Approval: April 2025

Table of Contents

| | | |
|--|--|-----------|
| 1. | Introduction | 3 |
| 2. | Progressive Multifocal Leukoencephalopathy | 4 |
| 2.1 | Aetiology and Epidemiology | 4 |
| 2.2 | Pathology | 5 |
| 2.3 | PML in Natalizumab-Treated Patients | 5 |
| 2.4 | PML Risk Factors | 5 |
| 2.5 | Extending the Dosing Interval for PML Risk Mitigation | 8 |
| 2.6 | Recommended Patient Monitoring | 11 |
| 2.6.1 | Testing for Anti-JCV Antibodies | 11 |
| 2.6.2 | Recommended MRI Monitoring for Early Detection of PML | 12 |
| 2.7 | Diagnosis of PML | 14 |
| 2.7.1 | Important Considerations | 14 |
| 2.7.2 | Clinical Assessment | 15 |
| 2.7.3 | MRI Differentiation Between PML and MS Relapse | 16 |
| 2.7.4 | Laboratory Investigation | 17 |
| 2.8 | Management of PML | 18 |
| 2.8.1 | Treatment of Immune Reconstitution Inflammatory Syndrome | 18 |
| 2.9 | Prognosis of PML | 19 |
| 2.10 | PML Diagnosed After Discontinuation of Natalizumab | 20 |
| 3. | Educational Guidance | 20 |
| 3.1 | Informing Patients About Benefits and Risks | 20 |
| 3.2 | Patient Alert Card | 21 |
| 3.3 | Treatment Forms | 21 |
| 4. | References | 22 |
| Appendix 1 Patient Alert Card | | 25 |
| Appendix 2 Treatment Initiation, Continuation and Discontinuation Forms | | 26 |

Table of Figures

| | |
|---|----|
| Figure 1: PML Risk Estimates Algorithm | 7 |
| Figure 2: Cumulative PML Risk Over Time for Anti-JCV Antibody-Positive Patients | 8 |
| Figure 3: Kaplan-Meier Estimates of the Cumulative Risk of PML for Primary | 10 |
| Figure 4: Recommended patient monitoring | 13 |
| Figure 5: MRI Protocols | 13 |
| Figure 6: Clinical Features of MS and PML | 15 |
| Figure 7: Features Visualised on MRI | 16 |

1. Introduction

This guidance document has been developed for those physicians initiating and supervising patient treatment with TYRUKO (natalizumab) in accordance with the conditions of the Marketing Authorisations of the drug, in order to ensure its safe and effective use. It contains information to be used in conjunction with the TYRUKO Summary of Product Characteristics (SmPC) available from <https://www.medicines.org.uk/emc> and is supported by the Treatment Initiation Form, Treatment Continuation Form, and Treatment Discontinuation Form (Appendix 2). This guidance provides additional risk mitigation measures; for primary guidance, please see the SmPC.

This guide includes a copy of the Patient Alert Card (Appendix 1).

It is recommended that physicians initiating and supervising treatment with natalizumab should share relevant sections of this document with radiologists who are involved in the differential diagnosis of progressive multifocal leukoencephalopathy (PML).

The guidance document focuses primarily on PML, which currently remains the most important adverse reaction affecting patients treated with natalizumab. Other important safety issues associated with TYRUKO, and information about the patient populations suitable for treatment with TYRUKO, are fully described in the SmPC, and physicians should ensure that this guidance document is used together with the SmPC and package leaflet (PL).

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme. You can report via:

- the Yellow Card website www.yellowcard.mhra.gov.uk
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) for healthcare professionals

Alternatively you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Sandoz via adverse.event.uk@sandoz.com or

online through the pharmacovigilance intake (PVI) tool at <https://pvi1j.solutions.iqvia.com>. If you have a question about the product, please contact Medical Information on 01276 698101 or via email at mi.uk@sandoz.com.

When reporting, please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, product brand name and batch number.

2. Progressive Multifocal Leukoencephalopathy

Prescribers should be aware that opportunistic infections, including PML, may occur during natalizumab therapy. An opportunistic infection is an infection due to an organism that generally does not cause disease or that causes only mild or self-limited disease, for example, oesophageal candidiasis, mycobacterial infections, and disseminated viral infections.

Cases of PML have been reported in patients during natalizumab treatment and up to 6 months after the last dose of natalizumab. Patients and their caregivers need to be advised of symptoms that may be indicative of early PML and continue to be vigilant through the treatment duration and 6 months after discontinuation (see Section 3.2, Appendix 1, and Appendix 2).

If an opportunistic infection is suspected, dosing with natalizumab must be suspended until it can be excluded through further evaluations.

2.1 Aetiology and Epidemiology

PML is a subacute, evolving infectious disease of the CNS caused by John Cunningham virus (JCV). Cases have also been reported as a consequence of immunosuppressant (IS) treatment of patients with autoimmune disorders and solid organ transplant recipients.

PML affects the subcortical white matter and is caused by the reactivation of JCV, a human polyomavirus [Wollebo 2015]. Initial infection with JCV is thought to occur during childhood, after which the virus persists primarily in the kidneys. Infection with the archetypal virus does not cause disease. However, mutations in the noncoding region and then the capsid protein-coding region of the viral deoxyribonucleic acid (DNA) are thought to lead to a pathogenic form that can enter the brain and infect the CNS. When coupled with a compromised immune system, reactivation of this neurotropic virus can occur, resulting in PML.

A seroprevalence study utilising the serum anti-JCV antibody assay (STRATIFY JCV) in over 6000 patients with MS demonstrated the prevalence of anti-JCV antibodies to be approximately 55%. Anti-JCV antibody prevalence in the European Union (EU) was reported as ranging from 48.8% to 69.5% in a cross sectional study of patients with MS, irrespective of treatment [Bozic 2014]. In the MS population, anti-JCV antibody prevalence increased with age and was lower in women than in men in all cohorts tested. These findings are consistent with those reported in the literature in healthy adults that used similar methodologies [Bozic 2014]. In general, anti-JCV antibody prevalence did not appear to be affected by known risk factors such as prior IS use, prior exposure to natalizumab, or duration of natalizumab exposure.

2.2 Pathology

Replication of JCV in the brain causes a lytic infection of oligodendrocytes resulting in the widespread destruction of myelin. Microscopic lesions develop in the subcortical white matter, which enlarge and may coalesce with a characteristic pattern on magnetic resonance imaging (MRI) examination. Besides oligodendrocytes, JCV can also infect cerebellar granule cell neurons, resulting in JCV granule cell neuronopathy (GCN). JCV GCN is associated with mutations in the C-terminus of the JCV VP1 gene, coding for the major capsid protein. JCV GCN can occur in isolation or in combination with PML. There have been very rare reports of JCV GCN in patients receiving natalizumab [Agnihotri 2014; Schippling 2013].

2.3 PML in Natalizumab-Treated Patients

During extended premarketing authorisation trials, 2 cases of PML were reported in patients with MS and a full safety evaluation revealed 1 additional case in a clinical trial patient with Crohn's disease [Yousry 2006]. Patients with confirmed PML in the postmarketing setting are followed up for up to 24 months following diagnosis. Of the 839 natalizumab-treated patients with confirmed PML through 7th Aug 2020, the survival rate was 76% (634 patients are alive), and the mortality rate was 24% (205 patients died).

2.4 PML Risk Factors

All data available to characterise PML risk are from the IV route of administration. Considering the similar PD profiles, the same PML risk and relevant risk factors are assumed for the different routes of administration. The following risk factors have been associated with the development of PML during natalizumab therapy:

- **The presence of anti-JCV antibodies in blood or serum.** Patients who are anti JCV antibody positive are at an increased risk of developing PML compared with patients who are anti-JCV antibody negative. However, PML only occurs in a minority of patients who are anti-JCV positive because JCV infection is only one of several steps required for the development of PML. The anti-JCV antibody assay is of greatest utility in stratifying PML risk when a positive test result is used in combination with the other identified risk factors described below.
- **Treatment duration.** The risk of PML increases with natalizumab therapy duration, especially beyond 2 years.
- **Prior immunosuppressant therapy.** Patients who have a history of treatment with an IS prior to starting natalizumab are also at increased risk of developing PML.

Patients who have all 3 risk factors for PML (i.e., are anti-JCV antibody positive, have received more than 2 years of natalizumab therapy, and have received prior IS therapy) have a higher risk of PML. In anti-JCV antibody-positive, natalizumab treated patients who have not used prior IS therapies, the level of anti-JCV antibody response (index) is associated with the level of risk for PML (i.e., the risk is greater in those with a high antibody index compared with those with a low index). Currently available evidence suggests that the risk of PML is low at an index less than or equal to 0.9 and increases substantially above 1.5 for patients who have been receiving treatment with natalizumab for longer than 2 years [Ho 2017]. This data was obtained from use of the STRATIFY JCV DxSelect assay.

Irrespective of the presence or absence of PML risk factors, heightened clinical vigilance for PML should be maintained in all patients treated with natalizumab and for 6 months after discontinuation of therapy.

The PML Risk Estimates Algorithm (**Figure 1**) summarises PML risk by anti-JCV antibody status, prior IS use, and duration of natalizumab therapy (by year of treatment) and stratifies this risk by index value when applicable.

The PML Risk Estimates provided in Figure 1 are based on anti-JCV antibody index data obtained from use of the STRATIFY JCV DxSelect assay.

- *For anti-JCV antibody-negative patients:* PML risk estimates are based on data from approximately 125,000 natalizumab-exposed patients where the estimated incidence of PML for anti-JCV antibody-negative patients is 0.1/1000. Anti-JCV antibody-negative patients may still be at risk of PML for reasons such as a new JCV infection, fluctuating antibody status, or a false negative test result.
- *For anti-JCV antibody-positive patients:* Risk estimates were derived using the Life Table Method based on the pooled cohort of 21,696 patients who participated in the STRATIFY-2, TOP, TYGRIS, and STRATA clinical trials. The risk estimates from the Life Table Method are forward-looking in yearly intervals: for example, the risk estimate corresponding to the 25- to 36-month natalizumab exposure period is the PML risk estimated for the following year in patients treated with natalizumab for 24 months. The individual treatment length of each patient takes drop-outs into account (e.g., treatment discontinuation). A higher anti JCV antibody index is associated with an increased risk of PML.
- *For anti-JCV antibody-positive patients who have used IS previously:* These patients are at an increased risk of PML because prior IS use is recognised as an independent risk factor for PML. PML risk estimates for this patient population are based on natalizumab clinical trial data where prior IS use comprised the following 5 IS therapies: mitoxantrone, methotrexate, azathioprine, cyclophosphamide, and mycophenolate mofetil. The exact mechanism by which prior use of these 5 IS therapies lead to an increased PML risk during natalizumab treatment is unknown. In patients with prior IS, current data do not show an association between higher index and PML risk. The underlying biological explanation for this effect is unknown. Further stratification of PML risk by anti-JCV antibody index interval for patients with no prior use of IS was derived from combining the overall yearly risk with the antibody index distribution.




Figure 1: PML Risk Estimates Algorithm

IS = immunosuppressant; JCV = John Cunningham virus; PML = progressive multifocal leukoencephalopathy. Exposure is shown up to 72 months only as data beyond 6 years of treatment are scarce.

The anti-JCV antibody index values for the PML risk estimation may depend on the type of assay used for anti-JCV antibody testing. For testing using STRATIFY JCV® DxSelect®, Ho et al. 2017 published a risk estimate guidance with index values defined for natalizumab-treated patients based on data from > 20,000 MS patients, see Figure 1. An additional anti-JCV antibody assay, ImmunoWELL™ JCV IgG test, has been developed. The comparison between STRATIFY JCV® DxSelect®, and ImmunoWELL JCV IgG tests indicates a potential offset of up to 0.1 in index values (e.g. lower range: ≤ 0.8 , higher range: > 1.4 in the table above) when using the ImmunoWELL™ JCV IgG test.

Additionally, some physicians may find a Kaplan-Meier (KM) curve useful to provide a visual representation of cumulative PML risk over time using a time-to-event analysis (**Figure 2**). In the KM curve, PML risk estimates for a given timepoint represent the total cumulative risk up to that timepoint (for example, at the timepoint of 48 months, the risk estimate on the KM curve represents the total risk up to 48 months, not the risk between 24 months and 48 months). Like **Figure 1**, data for these analyses were also obtained from the pooled cohort of 21,696 patients who participated in the STRATIFY 2, TOP, TYGRIS, and STRATA clinical trials and also takes into account the individual treatment length of each patient with consideration of drop-outs (e.g., treatment discontinuation).




Figure 2: Cumulative PML Risk Over Time for Anti-JCV Antibody-Positive Patients Stratified by Prior IS

IS = immunosuppressant; JCV = John Cunningham virus; PML = progressive multifocal leukoencephalopathy.

Note: number of PML cases after 72 infusions: No Prior IS = 11, Prior IS = 4. For patients with missing data on anti-JCV antibody status and/or prior IS use, multiple imputation methodology is used to impute the status.

(a) Average number of subjects who were in the study and did not have the event at the end of the specified time over multiple imputations. (b) Cumulative number of PML cases at the end of the specified time.

Source: TYSABRIMS/PRAC-ART20/POOLED/F-TTPML-KM-PRIORIS-MI5-V2-SAS

2.5 Extending the Dosing Interval for PML Risk Mitigation

It should be noted that the only approved dosing interval for natalizumab is 300 mg administered once every 4 weeks (Q4W, standard interval dosing (SID)). Refer to the SmPC Section 4.2 (Posology and method of administration) for the currently approved dosing.

The analysis of US anti-JCV antibody-positive natalizumab patients (TOUCH registry) suggests that there is a significant reduction in the risk of associated PML in anti-JCV antibody positive patients treated with an average natalizumab dosing interval of approximately 6 weeks (Q6W), so-called extended interval dosing (EID), compared with standard interval dosing (SID) (refer to the SmPC Section 5.1 [Pharmacodynamic effects]). In accordance with SmPC Section 4.4 (Special warnings and precautions for use), caution is required if extending the dosing interval of natalizumab as no prospective randomised controlled clinical trials have been completed to evaluate the efficacy of Q6W dosing, and the benefit/risk ratio for any dosing interval other than Q4W has not been established. The efficacy, tolerability, and safety of extending the dosing interval to every 6 weeks in patients who are stable on 4 weekly dosing for ≥ 1 year is currently being studied in a prospective, randomised, controlled clinical trial (NOVA Study 101MS329, <https://clinicaltrials.gov>, NCT03689972).

All information available to date on EID efficacy and safety come from evaluation of the IV route of administration. There are no data available on either the safety or efficacy of EID with SC route of administration and thus neither the benefits nor risks of EID SC has been established.

Summary results from real-world data on extended interval dosing

In 2017, a prespecified, retrospective analysis of anti-JCV antibody positive patients receiving natalizumab in the United States (US) was conducted to compare the risk of PML between patients who received SID and those who received EID. Three distinct analyses of EID versus standard interval dosing were performed. Each analysis represented a different real-world clinical practice scenario of extending the interval between doses. The analyses used different inclusion criteria (definitions) for patients on EID based on the number of doses received during specified time periods to test different hypotheses about the potential effect of EID on PML risk [Ryerson 2019]. EID PML cases were only observed for the primary and secondary definitions.

The primary definition identified EID based on the last 18 months of natalizumab exposure. Analyses showed that the majority of EID patients had received SID during the first 18 months of natalizumab exposure. In the last 18 months of natalizumab treatment the median number of doses received by EID patients was 13 or approximately one dose every 42 days (6 weeks). The secondary definition identified EID periods of ≥ 6 months occurring at any time during the treatment history with the majority of patients included having switched to EID after > 1 year of the SID (median 25 infusions). KM estimates of time to PML and the probability of developing PML for EID versus SID are presented in **Figure 3**. The analyses concluded that EID treatment after a period of SID treatment is associated with a lower risk of PML than SID treatment in anti-JCV antibody positive patients. Efficacy data were not available within this dataset, preventing any conclusions on EID benefit/risk. Even though the risk of PML in EID patients may be lower according to this analysis, patients treated with EID should receive monitoring for PML following the same guidance as that provided for patients treated in accordance with SID.




Figure 3: Kaplan-Meier Estimates of the Cumulative Risk of PML for Primary (A) and Secondary (B) EID Analyses

CI = confidence interval; EID = extended interval dosing; HR = hazard ratio; PML = progressive multifocal leukoencephalopathy; SID = standard interval dosing.

^a EID versus SID Cox model includes age, sex, prior use of immunosuppressant therapy, EID/SID group, and calendar year at the start of NATALIZUMAB therapy as covariates.

^b Number of patients who were still in the study and did not have PML at the end of the specified time. ^c Cumulative number of PML cases at the end of the specified time.

Results from efficacy modelling data

Models of pharmacokinetics (PK), pharmacodynamics (PD), and efficacy from clinical trial data developed by the originator suggest that the efficacy of Q6W dosing is comparable to that of SID in patients who were switched to EID after ≥ 1 year of SID treatment [Chang 2020].

Consistently, publications reported that treatment with longer dosing intervals in clinical practice had similar effectiveness in patients who initially received Q4W dosing and subsequently switched to longer dosing intervals [Bomprezzi and Pawate 2014; Yamout 2018; Zhovtis Ryerson 2019]. PK/PD/efficacy models using data (n = 175) from RESTORE [Fox 2014], which included only patients who had ≥ 1 year of SID treatment without relapse in the prior year, were developed to explore the risk of MS relapse for patients with different body weights (40-59 kg, 60-79 kg, 80-99 kg, 100-120 kg) and dosing intervals (Q5W, Q6W, Q7W, and Q8W). The models suggest that the risk of return of MS disease activity for patients switching to longer dosing intervals increases with length of dosing interval (especially ≥ 7 weeks) and body weight (especially ≥ 80 kg) [Chang 2020]. No prospective studies have been completed to validate these models. It is recommended that physicians monitor any patients who switch to longer dosing intervals, and particularly those patients with higher body weight (≥ 80 kg), for potential signs of return of MS disease activity. Previous exposure/response models [Muralidharan 2017] suggested that efficacy would be lower if patients initiated natalizumab with dosing other than 300 mg Q4W, but these models do not represent outcomes associated with initiating natalizumab as Q4W dosing and later switching to longer dosing intervals.

2.6. Recommended Patient Monitoring

2.6.1. Testing for Anti-JCV Antibodies

Testing serum for anti-JCV antibodies provides supportive information for risk stratification of natalizumab therapy. Testing for serum anti-JCV antibodies prior to initiating natalizumab therapy is recommended. Anti-JCV antibody-negative patients may still be at risk of PML for reasons such as a new JCV infection, fluctuating antibody status, or a false-negative test result. Retesting of anti-JCV antibody negative patients every 6 months is recommended. Retesting low index patients who have no history of prior IS use once they reach 2 years of treatment point is recommended to inform on appropriate patient MRI monitoring.

In the STRATIFY-1 clinical study, approximately 11% of patients changed serostatus from anti-JCV antibody negative to positive each year. Approximately 12-16% change serostatus from antibody negative to positive in the second-generation assay reported in Unilabs real world data over a median duration of 12 months. In the STRATIFY-2 clinical study, approximately 6% of patients changed serostatus from anti-JCV antibody positive to negative each year. Please note that this data was obtained from use of the STRATIFY JCV DxSelect assay.

Patients who test as positive for anti-JCV antibodies at any time should be considered to be at an increased risk for developing PML, independent from any prior or subsequent antibody test results.

Testing should only be performed using an appropriate and validated assay. The anti-JCV antibody assay should not be used to diagnose PML.

The use of plasmapheresis/plasma exchange (PLEX) or intravenous immunoglobulin (IVIg) can affect meaningful interpretation of serum anti-JCV antibody testing. Patients should not be tested for anti-JCV antibodies within 2 weeks of PLEX due to removal of antibodies from the serum, or within 6 months of IVIg treatment (i.e., 6 months = 5× half-life for immunoglobulins).

2.6.2. Recommended MRI Monitoring for Early Detection of PML

In clinical practice, MRI has been shown to be a useful tool for monitoring patients with MS. It may assist in differentiating PML lesions from MS plaques in patients who develop new neurological symptoms or signs once on therapy. Frequent MRI surveillance in patients at high risk of PML may lead to an earlier diagnosis of PML and better clinical outcomes [Prosperini 2016; Scarpazza 2019; Wattjes 2015].

Recommendations for MRI monitoring are summarised below:

1) Before initiation of treatment with natalizumab, a recent (usually within 3 months) full MRI (**Figure 5**) should be available as a reference and be repeated at least on a yearly basis. Physicians should evaluate the yearly full MRI in all patients receiving natalizumab for any signs of PML.

2) More frequent MRIs (e.g., on a 3- to 6-monthly basis) using an abbreviated protocol (**Figure 5**) should be considered for patients at a higher risk of PML. This includes the following:

- Patients who have all 3 risk factors for PML (i.e., are anti-JCV antibody positive **and** have received more than 2 years of natalizumab therapy **and** have received prior IS therapy).

Or

- Patients with a high anti-JCV antibody index who have received more than 2 years of natalizumab therapy and without prior history of IS therapy.

3) MRI should be performed at the first sign of any symptoms indicative of the possibility of PML.

Current evidence suggests that the risk of PML is low at an index less than or equal to 0.9 and increases substantially above 1.5 for patients who have been receiving treatment with natalizumab for more than 2 years. MRI monitoring decisions should take this information into consideration; physician discretion is advised for those patients with index values between 0.9 and 1.5.

As mentioned previously, an additional anti-JCV antibody assay, ImmunoWELL™ JCV IgG test, has been developed. The comparison between STRATIFY JCV DxSelect*, and ImmunoWELL JCV IgG tests indicates a potential offset of up to 0.1 in index values (e.g. lower range: ≤0.8, higher range: >1.4 in Figure 1) when using the ImmunoWELL™ JCV IgG test. *STRATIFY JCV® is a trademark of Biogen MA Inc. DxSelect® is a trademark of DIASORIN S.p.A.

A summary of the recommended monitoring is provided in **Figure 4**




Figure 4: Recommended patient monitoring

DWI = diffusion-weighted imaging; FLAIR = fluid-attenuated inversion recovery;
JCV = John Cunningham virus; MRI = magnetic resonance imaging.

Scanner field strength > 1.5 T, slice thickness ≤ 5 mm with no gap and with whole brain coverage. Axial images prescribed from the subcallosal line.

| Full MRI Protocol ¹ | Abbreviated MRI protocol ² |
|---|---|
| <ul style="list-style-type: none"> • Sagittal and axial 2D FLAIR or 3D FLAIR • Axial FSE proton density/T2 • Axial DWI with ADC • Axial SE T1-weighted pre- and post contrast or 3D T1-weighted pre- and post-contrast • Gd injection 0.1 mmol/kg over 30 seconds • 5-minute delay after contrast injection | <ul style="list-style-type: none"> • Sagittal and axial 2D FLAIR or sagittal 3D FLAIR with axial and coronal reformat • Axial FSE proton density/T2 • Axial DWI with ADC |

Figure 5: MRI Protocols

¹ Baseline and routine annual scans for all patients.

² Safety monitoring in high-risk patients.

2D = 2 dimensional; 3D = 3 dimensional; ADC = apparent diffusion coefficient;

DWI = diffusion weighted imaging; FLAIR = fluid-attenuated inversion recovery;

FSE = fast spin echo; Gd = gadolinium; MRI = magnetic resonance imaging; SE = spin echo.

If MRI lesions suggestive of PML are detected, the full MRI protocol should be extended to include contrast-enhanced T1-weighted imaging to detect inflammatory features and the possible coincidence of PML and PML-immune reconstitution inflammatory syndrome (IRIS), particularly during follow-up. It is also recommended that upon request for follow-up MRI, treating physicians inform radiologists that PML or other opportunistic infections are being considered in the differential diagnosis.

2.7. Diagnosis of PML

The consensus statement on PML diagnostic criteria published by the American Academy of Neurology requires clinical, radiographic, and virologic findings or typical histopathological findings and the presence of JCV [Berger 2013]. These criteria obviate the need for a brain biopsy but require compatible clinical and MRI findings plus detection of JCV DNA in the cerebrospinal fluid (CSF) by polymerase chain reaction (PCR) for a definite PML diagnosis; however, based on an alternative classification system, physicians are advised that in natalizumab-treated patients with MS, diagnosis of PML can be considered confirmed in the absence of clinical symptoms [Dong-Si 2014] (see Section 2.7.4).

All cases of PML should be reported directly via the MHRA. You can report via:

- the Yellow Card website www.yellowcard.mhra.gov.uk
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) for healthcare professionals

Alternatively you can report to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Sandoz via adverse.event.uk@sandoz.com or online through the pharmacovigilance intake (PVI) tool at <https://pvi1j.solutions.iqvia.com>. If you have a question about the product, please contact Medical Information on 01276 698101 or via email at mi.uk@sandoz.com.

2.7.1. Important Considerations

All natalizumab treated patients should have regular clinical follow-up to allow for early detection of changes in neurological status. **If any new neurological symptoms in patients treated with natalizumab develop, PML should always be considered as a diagnosis.**

Patients and their partners and caregivers need to be advised of symptoms that may be indicative of early PML (see Section 3.2, Appendix 1, and Appendix 2) and receive counselling on the need to be vigilant for these symptoms while the patient is receiving natalizumab therapy and for approximately 6 months after the last dose of natalizumab (PML has been reported up to 6 months after the last dose of natalizumab in patients who did not have findings suggestive of PML at the time of discontinuation).

In all cases where further investigation of change in neurological status or change in brain MRI is indicated, natalizumab must be suspended and not restarted until non-MS pathology has been confidently excluded. Suspension of natalizumab therapy for a short duration (days or weeks) is not expected to compromise therapeutic efficacy based on the PD of the drug (see Section 2.5).

Natalizumab dosing should only be restarted when the diagnosis of PML is confidently excluded (if necessary, by repeating clinical, MRI, and laboratory investigations if suspicion of PML remains).

The decision to suspend natalizumab may be based on the initial clinical presentation, MRI findings, the evolution of symptoms or signs, and/or the response to corticosteroid treatment.

Natalizumab should be permanently discontinued if PML is confirmed.

2.7.2 Clinical Assessment

Any new or recurrent neurological symptoms should require prompt and careful evaluation in order to ascertain the underlying pathology. In a patients whose MS disease activity has been stable on natalizumab, such changes warrant a clinical suspicion of PML (or other opportunistic infection). It is important to note that the presence of new onset neurologic symptoms is not required to diagnose PML (in the setting of other confirmatory evidence) and cases of asymptomatic PML have been reported. In both high- and low risk asymptomatic patients, any new suspected lesion on MRI should be carefully evaluated, particularly when an abbreviated protocol has been performed (see Section 2.7.3).

Figure 6 highlights the clinical features that may help differentiate MS lesions from PML. It should be noted that the table is not all inclusive and that symptomatic overlap between symptoms of these conditions exists. **Physicians should be aware that the clinical features of PML or other opportunistic infections can be difficult to distinguish from MS, especially early in the evolution of PML.** The history and pattern of previous and current symptoms and signs are important to note and will facilitate the management of patients.

| | Features indicative of: | |
|-----------------------|---|---|
| | MS | PML |
| Onset | Acute | Subacute |
| Evolution | <ul style="list-style-type: none"> • Over hours to days • Normally stabilise • Resolve spontaneously even without therapy | <ul style="list-style-type: none"> • Over weeks • Progressive |
| Clinical Presentation | <ul style="list-style-type: none"> • Diplopia • Paraesthesia • Paraparesis • Optic neuritis • Myelopathy | <ul style="list-style-type: none"> • Aphasia • Behavioural or cognitive changes and neuropsychological alteration • Retrochiasmal visual deficits • Marked weaknesses • Hemiparesis • Sensory deficits • Vertigo • Seizures • Ataxia (for GCN) |

Figure 6: Clinical Features of MS and PML

GCN = granule cell neuronopathy; MRI = magnetic resonance imaging;

MS = multiple sclerosis; PML = progressive multifocal leukoencephalopathy.

Note: PML may present with other clinical features not specified in this table. PML can be detected by MRI prior to the onset of clinical features. Some overlap of clinical features of MS and PML may occur. Reference: [Kappos 2011]

If PML is considered in a differential diagnosis, further investigations, including MRI evaluation (**Figure 7**) and lumbar puncture and CSF evaluation, should be undertaken as soon as possible. Natalizumab dosing should be suspended until PML (or another opportunistic infection) can be ruled out. Symptoms of JCV GCN are similar to symptoms of PML (i.e., cerebellar syndrome).

In JCV GCN, serial MRI of the brain shows severe progressive cerebellar atrophy over several months and JCV DNA is detected in the CSF. Natalizumab therapy should be suspended if JCV GCN and/or PML is suspected and permanently discontinued if a diagnosis of JCV GCN and/or PML is confirmed.

2.7.3. MRI Differentiation Between PML and MS Relapse

A full MRI protocol (**Figure 5**), preferably with and without contrast for the follow-up of patients receiving natalizumab, is proposed to obtain the best possible images to assist with clinical decision making [Yousry 2006; Yousry 2012]. Fluid attenuated inversion recovery (FLAIR) is the most sensitive sequence for detection of PML [Wattjes 2015].

Diffusion-weighted imaging sequences may also be helpful in distinguishing new lesions from chronic MS plaques and MRI changes from a previous scan [Wattjes 2015]. The MRI sequence parameters for each scanner should be selected for good representation of CNS anatomy and visualisation of MS lesions. Consistent use of the standard MRI protocol will help with recognition of early alterations on MRI (**Figure 7**).

The figure below shows features to be considered in the differential diagnosis of MS and PML

| Feature | MS | PML |
|---------------------------------|---|---|
| Lesion location | Focal, periventricular, or deep white matter. Lesions occur in all areas of the brain, optic nerves, and spinal cord. | Asymmetric, focal, or multifocal. Subcortical or diffuse white matter, cortical grey matter, and deep grey matter, brainstem, middle cerebellar peduncles. PML is not seen in spinal cord or optic nerves. |
| Lesion shape and lesion borders | Ovoid or flame shape; sharp borders, often perilesional oedema. | Irregular shape, finger-like projections toward the cortex. Ill-defined border toward the white matter, sharp border toward the grey matter. |
| Mode of extension | Initial enlargement over days or weeks and decrease in size within months. | Progressive increase in size. |
| Mass effect | Large acute lesions may have mass effect. | No mass effect. |

Figure 7 continued on next page

| Feature | MS | PML |
|---------------------------------------|---|---|
| T2-weighted images | Homogeneous hyperintensity with surrounding oedema. | Diffuse hyperintensity often with punctate microcystic inclusions. Perilesional nodules in the vicinity of the primary lesion (Milky Way galaxy). |
| T1-weighted images | Acute lesions: hypointense or isointense. Increasing signal intensity over time. | Isointense to hypointense at onset with decreasing signal intensity over time. |
| FLAIR images | Hyperintense, sharply delineated. | Hyperintense. Most sensitive sequence for detection of PML. |
| Contrast enhancement in acute lesions | Homogeneous nodular, ring or open ring enhancement conforms to shape and size of the lesion. Resolution over 1-2 months. | 43% of lesions show enhancement at the time of presentation. Patchy or nodular appearance. Enhancement does not conform to size or shape of the lesion. Increased enhancement with IRIS. |
| DWI | Acute lesions hyperintense. Chronic lesions isointense. | Acute lesions hyperintense. Distinguishes new PML lesions within areas of chronic white matter disease. No restriction on ADC. |
| Atrophy | Diffuse atrophy with progressive MS disease. | Post PML-IRIS –encephalomalacia and diffuse brain atrophy in the affected areas. |

Figure 7: Features Visualised on MRI

ADC = apparent diffusion coefficient; DWI = diffusion-weighted imaging;
FLAIR = fluid-attenuated inversion recovery; IRIS = immune reconstitution inflammatory syndrome;
MRI = magnetic resonance imaging; MS = multiple sclerosis;
PML = progressive multifocal leukoencephalopathy. References: [Kappos 2011;
Wattjes and Barkhof 2014; Yousry 2012]

2.7.4. Laboratory Investigation

The detection of JCV DNA by PCR in the CSF confirms the diagnosis of PML in patients with appropriate and associated MRI findings. However, a negative JCV PCR result should not exclude a possible diagnosis of PML, particularly because small volume lesions are associated with lower viral copy numbers [Wijburg 2018]. If JCV DNA is not detected in CSF and if clinical or MRI-based suspicion of PML persists despite a local or reference laboratory result being negative (i.e., not detected) for JCV DNA by PCR, a repeat lumbar puncture is recommended. Brain biopsy to detect JCV should be considered if JCV DNA is not detected in CSF on repeat testing, especially if the result is based on an assay with a limit of detection (LoD) that is higher than 11 copies/mL. Assays should be based on quantitative real-time PCR methodology to maximise sensitivity and specificity for detection, and it is recommended to use an assay with an LoD of at least 11 copies/mL. This level of detection is diagnostically relevant because PML has been confirmed in patients with low copy numbers in the CSF.

CSF samples should be analysed as quickly as possible to facilitate the diagnosis of PML. Additional support with regards for CSF analysis for PML diagnostic purposes is available and could be provided by the company. For additional support please use the below contact details: Sandoz Limited via: Tel: +44 (0)1276 698 101
Email: mi.uk@sandoz.com

2.8. Management of PML

Immune reconstitution

The data available suggest that early PML recognition is important for an optimal clinical outcome [Clifford 2015; Kappos 2019].

PLEX and/or immunoadsorption (IA) has been reported for rapid removal of natalizumab from the body with the intention of accelerated restoration of CNS immunosurveillance. However, based on a retrospective analysis of natalizumab treated patients, no difference was observed on 2-year survival after PML diagnosis between patients who received PLEX and those who did not [Kappos 2019]. Physicians should use medical judgement when considering the use of PLEX to treat PML. And, if PLEX is used, patients should be closely monitored for the development of IRIS (see Section 2.8.1), which occurs in almost all patients treated with PLEX and appears to occur more rapidly than in patients who are not treated with PLEX [Carruthers and Berger 2014; Clifford 2010].

Antivirals and other adjuvants

To date, no clinical trial has demonstrated a beneficial effect of antiviral agents in the management of PML. Real-world reports of PML outcomes associated with use of antivirals, including mefloquine, mirtazapine, and filgrastim, are mixed and inadequate to recommend any treatment approach [Kappos 2019; Williamson and Berger 2017].

2.8.1. Treatment of Immune Reconstitution Inflammatory Syndrome

IRIS occurs in almost all natalizumab-associated PML patients after withdrawal or removal of the medicinal product. IRIS is thought to result from the restoration of immune function in patients with PML, which can lead to serious neurological complications and may be fatal. Monitoring for development of IRIS and appropriate treatment of the associated inflammation during recovery from PML should be undertaken.

IRIS is generally suspected when patients with PML exhibit signs of clinical worsening usually, but not always, accompanied by gadolinium enhancement of PML lesions with or without mass effect on brain MRI. The clinical worsening is a result of a local inflammatory reaction, including oedema, and manifests as a worsening of neurological symptoms including hemiparesis, ataxia, speech abnormalities, visual disturbance, cognitive/behavioural changes, and seizures (dependent on the site of IRIS). Severe sequelae can occur including coma and death. Although JCV load in the CSF might be expected to decline in the setting of IRIS, it is also possible that due to the breakdown of the blood-brain barrier and release of JCV from cells lysed during IRIS, it can be increased.

It may become necessary to treat the active immune reaction to prevent potential damage caused by IRIS [Elston and Thaker 2009], but it can be life threatening and may therefore require management in an intensive care unit. Therefore, following PLEX or IA, periodic clinical monitoring of patients, including MRI monitoring, may be useful for the early detection of IRIS. The diagnosis and management of IRIS is a controversial issue and there is no consensus concerning its treatment. However, it has been suggested that corticosteroids may be useful to treat IRIS, particularly in patients with severe to life-threatening IRIS [Clifford 2015]. The following steroid regimens have been reported for the treatment of IRIS in the literature:

- 1) Oral prednisone 1.5 mg/kg/day for 2 weeks with a taper over 2 months.
- 2) Intravenous methylprednisolone (1 g/d for 3 or 5 days) with oral taper over 2 months [Williamson and Berger 2017].

If further deterioration occurs during the steroid taper and this is judged to be due to continuing or new inflammatory reactions, a further course of higher dose steroids may be necessary. Prophylactic steroid treatment is currently not recommended [Antoniol 2012; Scarpazza 2017].

2.9. Prognosis of PML

Improved survival from PML after natalizumab therapy has been associated with a younger age at PML diagnosis, less functional disability before PML diagnosis, a lower JCV load at PML diagnosis, and more localised brain involvement on MRI at diagnosis [Dong-Si 2015]. Furthermore, asymptomatic patients at PML diagnosis have been reported to have better survival and less functional disability than symptomatic patients at PML diagnosis [Dong-Si 2014; Prosperini 2016]. For information on outcomes associated with PLEX, see Section 2.8.

Asymptomatic PML (with a comparison to symptomatic PML)

Cases of asymptomatic PML have been reported that were initially suspected based on MRI findings and later confirmed by positive JCV DNA in the CSF. Asymptomatic PML patients had a shorter time from suspicion of PML to diagnosis of PML compared with symptomatic PML patients (median of 11 days versus 30 days, respectively). In addition, asymptomatic PML patients had more localised PML on brain MRI at the time of suspicion compared with symptomatic PML patients. There was a higher proportion of asymptomatic PML patients who had unilobar PML lesions on MRI at the time of diagnosis compared with symptomatic PML patients (56.2% versus 36.9%, respectively). Conversely, 18.8% of asymptomatic patients had widespread PML on MRI compared with 40.8% of symptomatic patients. Asymptomatic PML patients also had a higher survival rate compared with symptomatic patients (92.2% versus 73.1%, respectively).

2.10. PML Diagnosed After Discontinuation of Natalizumab

PML has been reported after the discontinuation of natalizumab. Patients and physicians should remain alert for any new signs or symptoms that may be suggestive of PML for approximately 6 months after discontinuation, taking into account the switch to other MS disease-modifying treatments that are associated with a risk of PML.

As of 7th August 2020, a total of 102 confirmed cases of PML have been reported in patients where PML onset occurred more than 4 weeks after the last natalizumab infusion. Of the 102 cases where time from last infusion to onset of PML is known, the majority of cases (80.0%) occurred either prior to or within 3 months of the last infusion, and 101 cases (99%) occurred within 6 months of the last infusion.

3. Educational Guidance

Due to this increased risk of developing PML, with increasing treatment duration, the benefits and risks of natalizumab therapy should be individually reconsidered by the specialist physician and the patient. The patient should be reformed about the risks of PML with natalizumab after 24 months and should be instructed together with their partners and caregivers on early signs and symptoms of PML.

Patients who are discontinuing natalizumab therapy should also be informed that cases of PML have occurred in patients up to 6 months after the last dose of natalizumab, and the same monitoring protocol should be continued for approximately 6 months after discontinuation of natalizumab.

Patients should also be informed of the increased risk of opportunistic infections. A template Treatment Initiation Form, Treatment Continuation Form, and Treatment Discontinuation Form are provided in Appendix 2.

Further details are available from:

Sandoz Limited via: Tel: +44 (0)1276 698 101

Email: mi.uk@sandoz.com

3.1. Informing Patients About Benefits and Risks

The PL that is contained in each pack of natalizumab explains both benefits and risks in language designed specifically for patients to understand.

Physicians should counsel patients on the importance of uninterrupted dosing, particularly in the early months of treatment. Physicians should counsel pregnant women on the use of natalizumab during pregnancy taking into account the patient's clinical condition. This benefit/risk discussion should also cover the possible return of disease activity after stopping natalizumab and the monitoring of newborns for potential haematological abnormalities for patients exposed to natalizumab in the third trimester.

In addition, locally agreed templates for a Treatment Initiation Form, a Treatment Continuation Form at 24 months of treatment, and a Treatment Discontinuation Form describing specifically the risk of PML with natalizumab therapy and the importance of monitoring for PML are provided in Appendix 2. These forms should be signed, provided to and discussed with patients before initiation of treatment, after patient counselling at 24 months of treatment, and after discontinuation to ensure that patients are fully informed about the risk of PML. The physician should keep 1 copy of these forms, and 1 copy should be given to the patient.

3.2. Patient Alert Card

The Patient Alert Card (Appendix 1) must be issued to patients to fill out and carry with them. Partners and caregivers should also be made aware of the information provided in the Patient Alert Card. The Patient Alert Card includes a recommendation for patients to retain the card for a period of 6 months after the last dose of natalizumab therapy because signs and symptoms suggestive of opportunistic infections, including PML (e.g. changes in mood, behavior, memory, motor weakness, speech, or communication difficulties) may occur up to 6 months after discontinuation and patients and their partners and caregivers should report any suspect changes in neurological status during this time.

The card contains a space to provide contact information so that they can report these concerns. Their physician must complete this section when issuing the card.

Appendix 1 is only included to provide an example of what the Patient Alert Card looks like. Appendix 1 is not representative of the actual size and scale of the Patient Alert Card.

For hard copies of the Patient Alert Card please contact:

Sandoz Limited via: Tel: +44 (0)1276 698 101

Email: mi.uk@sandoz.com

The Patient Alert Card is also available from <https://www.medicines.org.uk/emc>.

3.3. Treatment Forms

Treatment forms (see Appendix 2) are included as part of the Physician Pack. Additional forms can be ordered from

Sandoz Limited via: Tel: +44 (0)1276 698 101

Email: mi.uk@sandoz.com

The SmPC is available from <https://www.medicines.org.uk/emc>.

4. References

- Agnihotri SP, Dang X, Carter JL, et al. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. *Neurology*. 2014;83(8):727-32.
- Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? *Neurology*. 2012;79(23):2258-64. Epub 2012/11/21.
- Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. *Neurology*. 2013;80(15):1430-8.
- Bompreszi R, Pawate S. Extended interval dosing of natalizumab: a two-center, 7-year experience. *Ther Adv Neurol Disord*. 2014;7(5):227-31.
- Bozic C, Subramanyam M, Richman S, et al. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial. *Eur J Neurol*. 2014;21(2):299-304. Epub 2013/11/30.
- Carruthers RL, Berger J. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice. *Mult Scler Relat Disord*. 2014;3(4):419-30. Epub 2014/02/08.
- Chang I, Muralidharan KK, Campbell N, et al. Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing. *J Clin Pharmacol*. 2020 Epub 2020/09/19.
- Clifford DB. Progressive multifocal leukoencephalopathy therapy. *J Neurovirol*. 2015;21(6):632-6. Epub 2014/09/17.
- Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. *Lancet Neurol*. 2010;9(4):438-446.
- Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. *J Neurovirol*. 2015;21(6):637-44. Epub 2015/03/14.
- Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. *Ann Clin Transl Neurol*. 2014;1(10):755-64. Epub 2014/10/09.
- Elston JW, Thaker H. Immune reconstitution inflammatory syndrome. *Int J STD*
- Fox RJ, Cree BA, De Seze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. *Neurology*. 2014;82(17):1491-8. Epub 2014/03/28.
- Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. *Lancet Neurol*. 2017 Epub 2017/09/29.

- Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurol.* 2011;10(8):745-58.
- Kappos L, McGuigan C, Derguss T, et al. Determinants of Clinical Outcomes for Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Presented at the ECTRIMS 2019; Stockholm, Sweden.
- Muralidharan KK, Steiner D, Amarante D, et al. Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis. *J Pharmacokinet Pharmacodyn.* 2017;44(3):263-275. Epub 2017/03/01.
- Prosperini L, de Rossi N, Scarpazza C, et al. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry. *PLoS One.* 2016;11(12):e0168376. Epub 2016/12/20.
- Ryerson LZ, Foley J, Chang I, et al. Reduced Risk of Progressive Multifocal Leukoencephalopathy (PML) Associated with Natalizumab Extended Interval Dosing (EID): Updated Analysis of the TOUCH® Prescribing Program Database. Presented at the American Academy of Neurology 71st Annual Meeting; 4-10 May 2019; Philadelphia, PA.
- Scarpazza C, Prosperini L, De Rossi N, et al. To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. *Ann Neurol.* 2017;82(5):697-705. Epub 2017/10/31.
- Scarpazza C, Signori A, Cosottini M, et al. Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate. *Mult Scler.* 2019:1352458519854162. Epub 2019/05/30.
- Schippling S, Kempf C, Buchele F, et al. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. *Ann Neurol.* 2013;74(4):622-6. Epub 2013/09/16.
- Tyruko SmPC available at: <https://www.medicines.org.uk/emc>
- Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. *Curr Opin Neurol.* 2014;27(3):260-70.
- Wattjes MP, Rovira A, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. *Nat Rev Neurol.* 2015;11(10):597-606. Epub 2015/09/15.
- Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. *JAMA Neurol.* 2018;75(7):827-833.
- Williamson EML, Berger JR. Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies. *Neurotherapeutics.* 2017;14(4):961-973.

- Wollebo HS, White MK, Gordon J, et al. Persistence and pathogenesis of the neurotropic polyomavirus JC. *Ann Neurol*. 2015;77(4):560-70. Epub 2015/03/06.
- Yamout BI, Sahraian MA, Ayoubi NE, et al. Efficacy and safety of natalizumab extended interval dosing. *Mult Scler Relat Disord*. 2018;24:113-116. Epub 2018/07/05.
- Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *N Engl J Med*. 2006;354(9):924-33.
- Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. *Ann Neurol*. 2012;72(5):779-87.
- Zhovtis Ryerson L, Hoyt T, Metzger R, et al. Radiographic disease activity in patients on natalizumab extended interval dosing. Presented at the ECTRIMS 2019; Stockholm, Sweden

Appendix 1 Patient Alert Card

(Appendix 1 is only included to provide an example of what the Patient Alert Card looks like. Appendix 1 is not representative of the actual size and scale of the Patient Alert Card. For hard copies please order from the contact details provided in Section 3.2).

TYRUKO
PATIENT
ALERT CARD

SANDOZ

Tyruko▼(natalizumab)

MIR ID: 284725
Date of MHRA approval: April 2025

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
This alert card contains important safety information that you need to be aware of before, during and after stopping treatment with TYRUKO.

- Show this card to any doctor involved with your treatment, not only to your neurologist.
- Please read the TYRUKO 'Patient Leaflet' carefully before you start using this medicine.
- Keep this card with you during TYRUKO treatment and 6 months after the last dose of TYRUKO, since side effects may occur even after you have stopped treatment with TYRUKO.
- Show this card to your partner or caregivers. They might see symptoms of PML that you might not notice, such as changes in mood or behaviour, memory lapses, speech and communication difficulties. You should remain aware of symptoms that might arise for up to 6 months after stopping TYRUKO treatment.

Marketing Authorisation Holder:

Sandoz Limited,
Park View,
Riverside Way,
Watchmoor Park,
Camberley,
Surrey,
GU15 3YL

Reporting of side effects:

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme, via the Yellow Card website www.mhra.gov.uk/yellowcard, the free Yellow Card app available in Apple App Store or Google Play Store, and also some clinical IT systems for healthcare professionals. Alternatively you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

By reporting side effects, you can help provide more information on the safety of this medicine.

Contact Details

Patient Name:

Treating Doctor:

Name:

Phone Number:

**Start date of
NATALIZUMAB treatment:**

Prior to treatment with TYRUKO

- You should not be treated with TYRUKO if you have a serious problem with your immune system.
- You should not take any other long-term medicines for your multiple sclerosis while receiving TYRUKO.

During treatment with TYRUKO

Progressive Multifocal Leukoencephalopathy (PML)

PML, a rare brain infection, has occurred in patients who have been given TYRUKO. PML usually leads to severe disability or death.

The risk of PML appears to increase with treatment duration, especially beyond 2 years.

The symptoms of PML may be similar to an MS relapse. Therefore, if you believe your MS is getting worse or if you notice any new symptoms while you are on TYRUKO treatment or for up to 6 months after stopping TYRUKO treatment, it is very important that you speak to your doctor as soon as possible. PML symptoms generally develop more slowly than those associated with an MS relapse (over days or weeks), and may be similar to your MS symptoms.

Signs include:

- Changes in mental ability and concentration,
- Behavioural changes,
- Weakness on one side of the body,
- Vision problems,
- New neurological symptoms that are unusual for you.

Management of PML requires immediately stopping TYRUKO treatment

Serious Infections

Other serious infections may occur with TYRUKO. Speak to your doctor as soon as possible if you think you have developed a severe, persistent infection, for example a persistent fever.

Date of MHRA approval: April 2025

Appendix 2 Treatment Initiation, Continuation and Discontinuation Forms

TYRUKO ▼ (natalizumab) TREATMENT INITIATION FORM

SANDOZ

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

This form should be read carefully before starting treatment with TYRUKO. Please follow the advice in this form to ensure that you are fully informed of, and understand the risk of PML (progressive multifocal leukoencephalopathy), IRIS (immune reconstitution inflammatory syndrome) and other important adverse effects of TYRUKO.

Before starting treatment with TYRUKO you should:

- **Read the Patient Leaflet which is included in each box of TYRUKO**
- **Read the Alert Card given to you by your doctor.**
- **Discuss with your doctor the benefits and the risks associated with this treatment**

The Patient Leaflet and the Alert Card contain important safety information about PML, a rare brain infection that has occurred in patients who have been given NATALIZUMAB, and which may lead to severe disability or death.

JC virus is a common virus which infects many people but does not normally cause noticeable illness. PML is associated with an uncontrolled increase of the JC virus in the brain, although the reason for this increase in some patients treated with NATALIZUMAB is unknown.

The risk of PML with natalizumab-treated patients is higher:

- If you have antibodies to the JC virus in your blood
- The longer that you are on treatment with NATALIZUMAB, especially if you have been on treatment for more than 2 years
- If you have taken an immunosuppressant (a medicine that reduces the activity of your body's immune system) at any time before starting NATALIZUMAB treatment

Your doctor should discuss the potential risk of developing PML with you before you start treatment with TYRUKO.

Your doctor may test your blood to check if you have antibodies to the JC virus before you start treatment with TYRUKO. Your doctor may repeat the test while you are on TYRUKO treatment to check if anything has changed. The risk of PML is higher if you have all the risk factors described above, or if you have not taken an immunosuppressant medication prior to starting NATALIZUMAB and have higher levels of antibodies to the JC virus and you have been on NATALIZUMAB for more than 2 years. Your doctor will monitor you more closely if you are at higher risk for PML.

You should discuss with your doctor if TYRUKO is the most suitable treatment for you before you start taking TYRUKO and when you have been taking TYRUKO for more than 2 years.

In patients with PML, a reaction known as IRIS (immune reconstitution inflammatory syndrome) is likely to occur after treatment for PML, as TYRUKO is removed from your body. IRIS may lead to your condition getting worse, including worsening of brain function.

The Patient Leaflet should be read each time that you take TYRUKO because it may have new information that is important to your treatment.

You should keep the Alert Card with you to remind you of the important safety information, in particular any symptoms you may develop which could possibly indicate PML. If appropriate, you should show the Alert Card to your partner or caregiver.

If you do not have the Patient Leaflet or the Alert Card, then please ask your doctor to provide them to you before you initiate your TYRUKO treatment.

Patient's Name (print)

Patient's Signature


Date

Doctor's Name (print)

Doctor's Signature

Date

PML risk estimation:



IS: Immunosuppressant

Anti-JCV antibody index values may depend on the assay used. The PML Risk Estimates provided above are based on anti-JCV antibody index data obtained from use of the STRATIFY JCV DxSelect assay.

An additional anti-JCV antibody assay, ImmunoWELL™ JCV IgG test, has been developed. The comparison between STRATIFY JCV® DxSelect® *, and ImmunoWELL JCV IgG tests indicates a potential offset of up to 0.1 in index values (e.g. lower range: 0.8, higher range: > 1.4 in the table above) when using the ImmunoWELL™ JCV IgG test.

*STRATIFY JCV® is a trademark of Biogen MA Inc. DxSelect® is a trademark of DIASORIN S.p.A.

Patients who are anti-JCV antibody negative

Based on the available data, if you do not have antibodies to JCV your chance of getting PML is 0.1/1000 (or 1 in 10,000) patients.

Patients who are anti-JCV antibody positive

If you do have antibodies to JCV, your risk of developing PML will vary depending on the duration of treatment with NATALIZUMAB, the level of anti-JCV antibodies in your blood and whether you have received prior treatment with an immunosuppressant medication. Your doctor will discuss the potential risk before you start treatment.

Reporting of side effects:

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme. You can report via:

- the Yellow Card website www.yellowcard.mhra.gov.uk.
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) for healthcare professionals

Alternatively you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours. When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

Date of MHRA Approval: April 2025

TYRUKO (natalizumab)

TREATMENT CONTINUATION FORM

SANDOZ

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

This form should be read carefully before continuing NATALIZUMAB treatment for more than 2 years. Although you have been receiving NATALIZUMAB for 2 years, it is important that you are reminded that the risk of PML increases beyond this time. Please follow the advice in this form to ensure that you are fully informed of, and understand the risk of PML (progressive multifocal leukoencephalopathy), IRIS (immune reconstitution inflammatory syndrome) and other important adverse effects of NATALIZUMAB.

Before continuing treatment with NATALIZUMAB you should:

- **Read the Patient Leaflet which is included in each box of TYRUKO**
- **Read the Alert Card given to you by your doctor**
- **Discuss with your doctor the benefits and the risks associated with this treatment**

The Patient Leaflet and the Alert Card contain important safety information about PML, a rare brain infection that has occurred in patients who have been given natalizumab, and which may lead to severe disability or death. PML is associated with an uncontrolled increase of the JC virus in the brain, although the reason for this increase in some patients treated with natalizumab is unknown. JC virus is a common virus which infects many people but does not normally cause noticeable illness.

The risk of PML with NATALIZUMAB is higher:

- If you have antibodies to the JC virus in your blood
- The longer that you are on treatment with NATALIZUMAB, especially if you have been on treatment for more than 2 years
- If you have taken an immunosuppressant (a medicine that reduces the activity of your body's immune system) at any time before starting NATALIZUMAB treatment

Your doctor should discuss the potential risk of developing PML with you before you continue treatment with NATALIZUMAB.

Your doctor may test your blood to check if you have antibodies to the JC virus before you continue treatment with NATALIZUMAB. Your doctor may repeat the test while you are on NATALIZUMAB treatment to check if anything has changed. The risk of PML is higher if you have all the risk factors described above, or if you have not taken an immunosuppressant medication prior to starting NATALIZUMAB and have higher levels of antibodies to the JC virus and you have been on NATALIZUMAB for more than 2 years. Your doctor will monitor you more closely if you are at higher risk for PML.

You should discuss with your doctor if NATALIZUMAB is the most suitable treatment for you before you continue NATALIZUMAB for more than 2 years.

In patients with PML, a reaction known as IRIS (immune reconstitution inflammatory syndrome) is likely to occur after treatment for PML, as natalizumab is removed from your body. IRIS may lead to your condition getting worse, including worsening of brain function.

The Patient Leaflet should be read each time that you take NATALIZUMAB because it may have new information that is important to your treatment.

You should keep the Alert Card with you to remind you of the important safety information, in particular any symptoms you may develop which could possibly indicate PML. If appropriate, you should show the Alert Card to your partner or caregiver.

If you do not have the Patient Leaflet or the Alert Card, then please ask your doctor to provide them to you before you receive your NATALIZUMAB treatment.

Patient's Name (print)

Patient's Signature


Date

Doctor's Name (print)

Doctor's Signature

Date

PML risk estimation:



IS: Immunosuppressant

Anti-JCV antibody index values may depend on the assay used. The PML Risk Estimates provided above are based on anti-JCV antibody index data obtained from use of the STRATIFY JCV DxSelect® assay.

An additional anti-JCV antibody assay, ImmunoWELL™ JCV IgG test, has been developed. The comparison between STRATIFY JCV® DxSelect® *, and ImmunoWELL JCV IgG tests indicates a potential offset of up to 0.1 in index values (e.g. lower range: @ 0.8, higher range: > 1.4 in the table above) when using the ImmunoWELL™ JCV IgG test.

*STRATIFY JCV® is a trademark of Biogen MA Inc. DxSelect® is a trademark of DIASORIN S.p.A.

Patients who are anti-JCV antibody negative

Based on the available data, if you do not have antibodies to JCV your chance of getting PML is 0.1/1000 (or 1 in 10,000) patients.

Patients who are anti-JCV antibody positive

If you do have antibodies to JCV, your risk of developing PML will vary depending on the duration of treatment with NATALIZUMAB, the level of anti-JCV antibodies in your blood and whether you have received prior treatment with an immunosuppressant medication. Your doctor will discuss the potential risk before you continue with treatment.

Reporting of side effects:

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme. You can report via:

- the Yellow Card website www.yellowcard.mhra.gov.uk
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) for healthcare professionals

Alternatively you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

Date of MHRA Approval: April 2025

TYRUKO ▼ (natalizumab)

TREATMENT DISCONTINUATION FORM

SANDOZ

This medicine is subject to additional monitoring. This will allow quick identification of new safety information..

This form should be read carefully before discontinuing treatment with TYRUKO. Please follow the advice in this form to ensure that you are fully informed of, and understand the continued risk of PML (progressive multifocal leukoencephalopathy) for up to 6 months following discontinuation of NATALIZUMAB.

Before starting treatment with TYRUKO you should have received an Alert Card from your doctor. This Alert Card should be kept for 6 months after discontinuation of treatment as it has important information about PML for your reference.

PML is a rare brain infection that has occurred in patients who have been given NATALIZUMAB, and which may lead to severe disability or death. PML has been reported up to 6 months after discontinuation of NATALIZUMAB.

Signs include:

- Changes in mental ability and concentration
- Behavioural changes
- Weakness on one side of the body
- Vision problems
- New neurological symptoms that are unusual for you

Symptoms of PML may be similar to an MS relapse. Therefore, if you believe your MS is getting worse or if you notice any new symptoms for up to 6 months after stopping NATALIZUMAB treatment, it is very important that you speak to your doctor as soon as possible.

During the 6 months following treatment discontinuation of NATALIZUMAB, your doctor will monitor you and will decide when you should receive MRI imaging. In general, you will continue to receive 3-6 month MRI imaging if you have either of the following combination of PML risk factors:

- You have antibodies to the JC virus, have taken NATALIZUMAB for more than 2 years and previously taken an immunosuppressant (a medicine that reduces the activity of your body's immune system) at any time before starting NATALIZUMAB
- You have never taken an immunosuppressant therapy before starting NATALIZUMAB, but have taken NATALIZUMAB for more than 2 years and have a high anti-JCV antibody index (increased amount of antibody in your blood)

If you do not fall into one of the above groups, then you will continue to receive routine MRIs as prescribed by your doctor.

Should you have any questions about the above information, please ask your doctor.

If you do not have the Alert Card that you received when starting TYRUKO, then please ask your doctor for a new card.

You should keep the Alert Card with you to remind you of the important safety information, in particular any symptoms you may develop which could possibly indicate PML, if appropriate, you should show the Alert Card to your partner or caregiver.

Patient's Name (print)

Patient's Signature

Date

Doctor's Name (print)

Doctor's Signature

Date

Reporting of side effects:

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme. You can report via:

- the Yellow Card website www.yellowcard.mhra.gov.uk.
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) for healthcare professionals


Alternatively you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.






Artwork Proof Box:


| | |
|-----------------|-----------------------------------|
| Variation: | N002 – Admin Changes |
| Proof no: | 002.0 |
| Date prepared: | 14/05/2025 |
| Font size: | 8 pt |
| Fonts: | FuturaCEEf, Helvetica, Myriad Pro |
| Dimension: | 210 x 297 mm |
| Technical data: | |
| SKUs: | 00000000 |
| SZ codes: | 00000000 |
| Item codes: | PG.1706.002.0d |
| Pharma codes: | 00000000 |

Technical Colours:

| | |
|---|---------|
|  | Legend: |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Colours:

| | |
|---|-------------|
|  | Pantone 541 |
|  | Cyan |
|  | Magenta |
|  | Yellow |
|  | Black |
| | |


SANDOZ



| | | |
|--|--|--|
| | | |
| | | |
| | | |